Strategic Account Lead - Rare Neurology (ALS)

Otsuka America Pharmaceutical Inc.; Helena (MT); À distance; USD 158 000 - 252 000; Plein temps

Avantages offerts par ce poste

Comprehensive benefits

Résumé du poste

Otsuka America Pharmaceutical Inc. seeks a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise, focusing on ALS centers, clinicians, and patient access programs.

The role is remote and field-based, requiring expert communication of complex data and strong cross‑functional collaboration. As the SAL, you will build relationships with HCPs, navigate access and site-of-care challenges, and help advance new therapies while evolving with the program pipeline.

Qualifications

• Understanding complex diseases and articulating complex clinical data.
• Educate on screening and diagnostic pathways, prioritizing treatment.
• Develop and maintain relationships with HCPs and KOLs.
• Explain access and patient support programs to prescribers.
• Present at conferences and scientific meetings on rare neurology.

Responsabilités

• Develop strategic account plans using insights from data sources and market intelligence.
• Engage ALS Centers of Excellence to identify key contacts and workflows.
• Navigate site-of-care, patient onboarding, and initiation barriers.
• Work with Market Access to address reimbursement and access specifics.
• Collaborate with cross-functional teams to meet objectives.

Connaissances

Clinical acumen

HCP engagement

Relationship building

Conferences education

Strategic planning

Market access

Cross-functional

Formation

Bachelor's degree

Description du poste

Otsuka America Pharmaceutical Inc. seeks a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise, focusing on ALS centers, clinicians, and patient access programs.

The role is remote and field-based, requiring expert communication of complex data and strong cross‑functional collaboration. As the SAL, you will build relationships with HCPs, navigate access and site-of-care challenges, and help advance new therapies while evolving with the program pipeline.